去纤苷的治疗效果怎么样？

(also called defibrinated sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). The most common adverse reactions of defibrinoside include hypotension, diarrhea, vomiting, nausea, and epistaxis. The most common serious adverse reactions include hypotension and alveolar hemorrhage. Today let’s take a closer look at the therapeutic effect of defibrotide? Richardson et al first explored the application of defibrotide (defibrotide) in the treatment of hepatic vein occlusion after hematopoietic stem cell transplantation (HSCT). The study included 19 patients with sHVOD. Give defibrinoside intravenous infusion, 5~60mg/kg per day, the median usage time is 15 days (2-61 days). The results showed that 42% of patients achieved complete remission (CR), and the 100-day overall survival (os) rate after transplantation reached 32%, and defibrotide was well tolerated by patients. Not only that, defibrotide (also called defibrotide sodium) has shown positive therapeutic effects in multiple clinical trials, and it also has a certain effect in the treatment of multiple myeloma. Its launch meets the treatment needs of this rare and fatal disease. The therapeutic effect of defibrotide has attracted the most attention since its launch. The use of heparin in the treatment of diseases such as hepatic venous occlusion often increases the patient's risk of bleeding. However, defibrination alone or in combination with heparin has not only achieved a good effect in preventing HVOD, but also has a very low incidence of side effects.

A multi-center randomized phase III clinical trial was completed in Europe. The trial included 356 stem cell transplant patients. The incidence of hepatic vein occlusion 30 days after transplantation was compared. There were 180 patients in the defibrotide group, 2 of whom developed hepatic vein occlusion, accounting for 12%; there were 176 patients in the control group, of which 35 developed hepatic vein occlusion, accounting for 20%. The use of defibrotide significantly reduced the incidence of the disease, and the effect was obvious. Defibrotide (also called defibrotide sodium) is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD.

The above is the content of the effect of (also called fiber-removing sodium), I hope it can help you!

Recommended related hot articles: /newsDetail/84588.html